Beren Therapeutics raised $300 million to support the potential commercial launch of adrabetadex, an FDA Breakthrough Therapy-designated cyclodextrin therapy under Priority Review for the treatment of infantile-onset Niemann-Pick disease type C, a rare and rapidly fatal pediatric neurodegenerative disorder.
